Parkinson's Disease Schedule of Activities (Years 0 - 5)

Visit Number		Screening	Baseline (BL)	V02	V04	V05	V06	R06	V08	R08	V10	R10	V12	[H]Event Driven Modified Visit
Assessment	**[**]Timepoint	-60 days	0	6 mths	12 (Y1)	18 mths	24 (Y2)	30 mths	36 (Y3)	42 mths	48 (Y4)	54 mths	60 (Y5)	---
Consent Activities														
Documentation of Informed Consent		X	As Needed											
Continuing Consent					X		X		X		X		X	
Research Proxy Designation		X	As Needed											
Consent to share contact information		X	As Needed											
Informed Consent Tracking Log		X	As Needed											
General Activities														
Demographics		X												
Family History		X												
Socio-Economics		X												
Physical Examination		I												
myPPMI Registration[S]		X	As Needed											
Vital Signs (Height and Weight BL + Annually)		X	X	X	X	X	X		X		X		X	
Review Inclusion/Exclusion Criteria		I	I											
Visit Status		X	X	X	X	X	X	X	X	X	X	X	X	
Screen Fail		As Needed												
Conclusion of Study Participation				As Needed										
Neurological/Motor Assessments														
Participant Motor Function Questionnaire			P		P		P		P		P		P	
Freezing and Falls			X		X		X		X		X		X	
PD Diagnosis History		I												
Neurological Examination		I			I		I		I		I		I	
Initiation of Dopaminergic Therapy				X	X	X	X	X	X	X	X	X	X	
MDS-UPDRS Part Ia			I	I	I	I	I		I		I		I	
MDS-UPDRS Part Ib and Part II			P	P	P	P	P	P	P	P	P	P	P	
MDS-UPDRS Part III Treatment Determination/Motor Exam/Hoehn & Yahr[d,e]			I	I	I	I	I		I		I		I	
MDS-UPDRS Repeat Part III/Hoehn & Yahr[b,d,e]			I	I	I	I	I		I		I		I	
MDS-UPDRS Part IV[b,d]			I	I	I	I	I		I		I		I	
Modified Schwab & England ADL			I	I	I	I	I		I		I		I	
Features of Parkinsonism			I	I	I	I	I		I		I		I	
Other Clinical Features			I	I	I	I	I		I		I		I	
Primary Research Diagnosis			I	I	I	I	I		I		I		I	
Clinical Global Impression (CGI)			I		I		I		I		I		I	

Parkinson's Disease Schedule of Activities (Years 0 - 5)

Visit Number		Screening	Baseline (BL)	V02	V04	V05	V06	R06	V08	R08	V10	R10	V12	[H]Event Driven Modified Visit
Assessment	**[**]Timepoint	-60 days	0	6 mths	12 (Y1)	18 mths	24 (Y2)	30 mths	36 (Y3)	42 mths	48 (Y4)	54 mths	60 (Y5)	---
Clinical Diagnosis			X	X	X	X	X	X	X	X	X	X	X	
Non-Motor Assessments														
REM Sleep Behavior Disorder Screening Questionnaire			P		P		P		P		P		P	
Epworth Sleepiness Scale			P		P		P		P		P		P	
SCOPA-AUT			P		P		P		P		P		P	
Participant Global Impression (PGI)			P		P		P		P		P		P	
PDAQ-27			P		P		P		P		P		P	
Neuro QoL			P		P		P		P		P		P	
Cognitive Assessments														
Montreal Cognitive Assessment*			X		X		X		X		X		X	
Clock Drawing*			X		X		X		X		X		X	
Lexical Fluency*			X		X		X		X		X		X	
Hopkins Verbal Learning Test-Revised*			X		X		X		X		X		X	
Benton Judgment of Line Orientation*			X		X		X		X		X		X	
Modified Semantic Fluency (Animals only)*			X		X		X		X		X		X	
Letter Number Sequencing*			X		X		X		X		X		X	
Symbol Digit Modalities Test*			X		X		X		X		X		X	
Trail Making Test (A and B)*			X		X		X		X		X		X	
Modified Boston Naming Test*			X		X		X		X		X		X	
Cognitive Change			P	P	P	P	P		P		P		P	
Cognitive Categorization			I		I		I		I		I		I	
Neuropsychological Assessments														
State-Trait Anxiety Inventory for Adults			P		P		P		P		P		P	
Geriatric Depression Scale			P		P		P		P		P		P	
QUIP			P		P		P		P		P		P	
Clinical and Biological Samples														
Clinical Lab blood sample		X												
Coag PT/PTT		X												
Research Biosamples (blood + urine)		X		X	X	X	X		X		X		X	
Lumbar puncture		X			X		X		X		X		X	
Skin biopsy		X[R]	X[i]				X				X			
Imaging Activities														
Pregnancy Test (prior to tracer injection), if applicable			X		X		X				X			

Parkinson's Disease Schedule of Activities (Years 0 - 5)

Visit Number	Screening	Baseline (BL)	V02	V04	V05	V06	R06	V08	R08	V10	R10	V12	[H]Event Driven Modified Visit
Assessment / **[**]Timepoint	**-60 days**	**0**	**6 mths**	**12 (Y1)**	**18 mths**	**24 (Y2)**	**30 mths**	**36 (Y3)**	**42 mths**	**48 (Y4)**	**54 mths**	**60 (Y5)**	---
Dopamine Imaging		X		X		X				X			
CT Scan	X[K]												
MRI	X[K]	X[j]				X				X			
Safety and General Health													
[#]Adverse Events	X	X		X		X		X		X		X	
Adverse Event Telephone Assessment	X	X		X		X		X		X		X	
Current Medical Conditions Review	X	X	X	X	X	X	X	X	X	X	X	X	
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	
LEDD Concomitant Medication Log	As Needed												
Participation in Other Studies	As Needed												
Procedure for PD Log		As Needed											
Report of Pregnancy	As Needed												

I = Investigator (or trained designee) completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

b=only completed for participants receiving dopaminergic treatment for PD

c =–Previously enrolled participants transitioning to new database may be asked to have skin biopsy. If not done at first visit, may be conducted at a subsequent in person visit.

d = Investigator or Coordinator may complete treatment and timing information.

e = If the participant is on levodopa, dopamine agonists, or has had DBS, the MDS-UPDRS Part III should be performed in the OFF and ON state.

H= see protocol section 11 for modification of visit schedule due to New Clinical Diagnosis, Need for PD Therapy or withdrawal from study

j = Do not collect at Baseline Visit if collected at Screening Visit

K= Optional if required by the site for pre-LP imaging.

R= Completed at Screening or Baseline based on site preference.

S= Site to inform about myPPMI and assist with registration, if not yet done.

*Completed on paper source first, and then scores entered into EDC

**Window of +45 days either side of Target Visit Date

Adverse events collected only day of and 2-3 business days post Dopamine Imaging, LP and skin biopsy per protocol.

As needed assessments can be located under the Event Driven category in EDC